Abbott Laboratories (ABT)
Abbott Laboratories (ABT) is a global healthcare company that develops, manufactures, and markets a wide range of healthcare products, including pharmaceuticals, diagnostic tools, medical devices, and nutritional products. Founded in 1888, Abbott is known for innovative solutions in medical diagnostics, cardiovascular and neurology devices, and nutrition, serving patients and healthcare providers worldwide.
Dividend History
Investors can expect a dividend payout of $0.59 per share, scheduled to be distributed in 58 days on November 17, 2025
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| November 17, 2025 | $0.59 | 2025-10-15 | 2025-10-15 |
| August 15, 2025 | $0.59 | 2025-07-15 | 2025-07-15 |
| May 15, 2025 | $0.59 | 2025-04-15 | 2025-04-15 |
| February 14, 2025 | $0.59 | 2025-01-15 | 2025-01-15 |
| November 15, 2024 | $0.55 | 2024-10-15 | 2024-10-15 |
Dividends Summary
- Abbott Laboratories has issued 88 dividend payments over the past 21 years
- The most recent dividend was paid 36 days ago, on August 15, 2025
- The highest dividend payed out to investors during this period was $0.59 per share
- The average dividend paid during this period was $0.36 per share.
Company News
The global Carcinoembryonic Antigen (CEA) market is projected to grow from $2.17 billion in 2025 to $3.45 billion by 2033, driven by rising cancer prevalence and advances in diagnostic technologies.
AbbVie is a pharmaceutical company with a strong dividend track record, growing payouts, and a robust drug development pipeline. While its stock isn't currently cheap, it offers promising long-term investment potential.
Abbott Laboratories reported better-than-expected Q2 sales and earnings but lowered full-year guidance, causing stock price to drop nearly 10%. Medical Devices sales grew 13.4%, with strong performance in Diabetes Care and Continuous Glucose Monitors.
Abbott Laboratories is well-positioned to withstand tariff impacts, with a diversified business and investments in domestic manufacturing facilities. The company's strong performance and positive analyst trends suggest it is on track to reach new highs in 2025.
Hims & Hers Health, Inc. (HIMS) has seen a 45.8% stock price increase in the past three months, outperforming the industry and broader market. The company's recent announcements, including the addition of GLP-1 injections to its weight loss portfolio and positive 2024 revenue outlook, have contributed to the stock's upward momentum.
